Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorRecep Tayyip Erdogan University Training and Research Hospital

About this trial

Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.

A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Being between 18 and 65 years of age

Being systemically healthy or diagnosed with hyperuricemia

Having at least 20 natural teeth

Being periodontally healthy or diagnosed with periodontitis

Disqualifiers

Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.

Smoking

Pregnancy or lactation

Having received periodontal treatment within the last 3-6 months

Trial population

Recep Tayyip Erdoğan University Faculty of Dentistry

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Collection of gingival crevicular fluid (GCF) and serum samples

    Other intervention

    Serum and GCF samples will be collected from participants in the first session

  • Measurement of periodontal clinical parameters

    Other intervention

    Periodontal clinical parameters will be measured from participants initially

Treatment groups

80 Participants
are divided into 4 treatment groups
Group A: Group 1: Individuals with periodontitis and hyperuricemia2 interventions
Group B: Group 2: Periodontally healthy individuals with hyperuricemia2 interventions
Group C: Group 3: Individuals with periodontitis but without hyperuricemia2 interventions
Group D: Group 4: Periodontally healthy individuals without hyperuricemia2 interventions

Trial outcomes

Primary outcomes

1

Periodontal pocket depth

The distance between the gingival margin and the base of the pocket will be measured in millimeters.

Time frame
at baseline
2

clinical attachment loss

The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.

Time frame
at baseline

Secondary outcomes

1

Level of interleukin-1 beta

Interleukin-1 beta levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

Time frame
at baseline
2

Level of interleukin-10

Interleukin-10 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

Time frame
at baseline
3

Level of interleukin-18

Interleukin-18 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

Time frame
at baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.